DelMar Pharmaceuticals (NASDAQ:DMPI) issued its earnings results on Thursday. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.03, Fidelity Earnings reports.
Shares of DelMar Pharmaceuticals stock remained flat at $$0.55 during trading hours on Friday. 5,909 shares of the company’s stock were exchanged, compared to its average volume of 241,726. The company’s fifty day simple moving average is $0.59 and its 200 day simple moving average is $0.71. The stock has a market cap of $6.04 million, a price-to-earnings ratio of -0.21 and a beta of 1.30. DelMar Pharmaceuticals has a 1-year low of $0.40 and a 1-year high of $6.29.
A number of research analysts have recently weighed in on DMPI shares. Zacks Investment Research upgraded DelMar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 29th. Maxim Group restated a “buy” rating on shares of DelMar Pharmaceuticals in a research report on Friday, November 15th.
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
Featured Story: What is a stock split?
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.